Literature DB >> 30779046

Phosphoproteomic Analysis of Signaling Pathways in Lymphomas.

Björn Häupl1,2, Henning Urlaub3, Thomas Oellerich4,5.   

Abstract

Cell fate decisions are controlled by complex signal transduction processes that transmit information via posttranslational protein modifications such as phosphorylation. In lymphoma, as in other cancer types, these signaling networks are often dysregulated and thus contribute to malignant transformation and tumor maintenance. For example, B-cell antigen receptor signals are rewired in certain lymphoma types, such as diffuse large B-cell lymphomas, to promote cell growth and survival of the malignant cell clones. Hence, global elucidation of such intricate signaling networks is important for an improved understanding of the biology of these tumors and the identification of target proteins for therapeutic purposes.We describe here a mass spectrometry-based phosphoproteomic approach for characterization of intracellular signaling events and their dynamics. This integrated phosphoproteomic technology combines phosphopeptide enrichment and fractionation with liquid-chromatography-coupled mass spectrometry for the site-specific mapping and quantification of thousands of phosphorylation events in a given cell type. Such global signaling analyses provide valuable insights into oncogenic signaling networks and can inform drug development efforts.

Entities:  

Keywords:  Antigen receptors; B-cell lymphomas; Mass spectrometry; Phosphoproteomics; Signaling

Mesh:

Substances:

Year:  2019        PMID: 30779046     DOI: 10.1007/978-1-4939-9151-8_19

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  AKT-dependent NOTCH3 activation drives tumor progression in a model of mesenchymal colorectal cancer.

Authors:  Julia Varga; Adele Nicolas; Valentina Petrocelli; Marina Pesic; Abdelrahman Mahmoud; Birgitta E Michels; Emre Etlioglu; Diego Yepes; Björn Häupl; Paul K Ziegler; Katrin Bankov; Peter J Wild; Stefan Wanninger; Hind Medyouf; Henner F Farin; Sabine Tejpar; Thomas Oellerich; Jürgen Ruland; Christian W Siebel; Florian R Greten
Journal:  J Exp Med       Date:  2020-10-05       Impact factor: 14.307

2.  IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era.

Authors:  Xiangli Chen; Yuzhu Zang; Dujuan Li; Jianmin Guo; Yacai Wang; Yuqi Lin; Zhenghong Wei
Journal:  Medicine (Baltimore)       Date:  2020-05-22       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.